![John R. Mcdonald](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
John R.
Mcdonald founded Osprey Pharmaceuticals Ltd.
in 1998, where he worked as VP-Science Operations & Intellectual Property from 2011 to 2012.
Dr. Mcdonald received his doctorate degree from Napier University.
Ehemalige bekannte Positionen von John R. Mcdonald
Unternehmen | Position | Ende |
---|---|---|
Osprey Pharmaceuticals Ltd.
![]() Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Gründer | 29.06.2012 |
Ausbildung von John R. Mcdonald
Napier University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Osprey Pharmaceuticals Ltd.
![]() Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Health Technology |